Page last updated: 2024-09-03

gefitinib and 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole

gefitinib has been researched along with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole in 2 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole)	Trials (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole)	Recent Studies (post-2010) (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole)
5,231	566	2,919	377	2	154

Protein Interaction Comparison

Protein	Taxonomy	3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (IC50)
Histone acetyltransferase p300	Homo sapiens (human)	1.3
Hypoxia-inducible factor 1-alpha	Homo sapiens (human)	2.935
CREB-binding protein	Homo sapiens (human)	1.3
Endothelial PAS domain-containing protein 1	Homo sapiens (human)	1.2

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Hu, H; Hu, MN; Li, JY; Miao, XK; Mou, LY; Xu, JJ; Yang, WL; Zhang, JY; Zhang, XW; Zhou, TX	1
Chen, M; Huang, F; Jiang, N; Jin, Q; Xu, X; Zheng, J	1

Other Studies

2 other study(ies) available for gefitinib and 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole

Article	Year
YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells. European journal of pharmacology, 2020, May-05, Volume: 874 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Protein Transport; Proteolysis	2020
HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib. Oxidative medicine and cellular longevity, 2021, Volume: 2021 Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mutation; Phosphorylation; Proto-Oncogene Proteins c-met; Tumor Stem Cell Assay; Wound Healing	2021

Article

Year

YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.

European journal of pharmacology, 2020, May-05, Volume: 874

Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; Protein Transport; Proteolysis

2020

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib.

Oxidative medicine and cellular longevity, 2021, Volume: 2021

Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mutation; Phosphorylation; Proto-Oncogene Proteins c-met; Tumor Stem Cell Assay; Wound Healing

2021